Syneron Inc. Reports Third Quarter 2009 Financial Results

YOKNEAM, ISRAEL--(Marketwire - November 09, 2009) - Syneron Medical Ltd. (NASDAQ: ELOS)

Recent highlights

-- Third consecutive quarter of gross margin improvement -- Return to positive cash flow from operating activities during the three-month period ending September 30, 2009 -- Sequential revenue growth in the seasonally weakest quarter -- DSOs fall for third consecutive quarter -- Inventories lowered for the third consecutive quarter -- Signed definitive agreement for merger transaction with Candela Corporation -- Completed acquisition of Primaeva Medical Inc. 

Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced financial results for the third quarter ended September 30, 2009.

Revenues for the third quarter of 2009 were $14.3 million, compared to revenues of $14.2 million in the second quarter of 2009, and revenues of $28.5 million for the third quarter of 2008.

Syneron’s gross margins improved for the third consecutive quarter. Gross margins widened to 67% in the third quarter from 64.8% in the second quarter of 2009. Syneron’s gross margin has risen by 12.3 percentage points since the fourth quarter of 2008.

Syneron recorded a net loss in the third quarter of $5.5 million on a GAAP basis which includes $0.7 million in stock-based compensation and approximately $1.2 million of expenses related to the merger of Syneron with Candela Corporation, announced on September 9, 2009. The third quarter net loss of $5.5 million compares to a similar net loss of $5.5 million in the second quarter of 2009 and a net profit of $2.2 million in the third quarter of 2008. The merger related expenses are included in the GAAP results in accordance with FASB statement number 141(R) “Business Combinations” which is effective for business combinations occurring after January 1, 2009. Syneron will continue to note merger related expenses on a quarterly basis until the transaction is completed.

On a non-GAAP basis, excluding stock-based compensation expenses, net loss in the third quarter was $4.8 million, compared to a net profit on a non-GAAP basis of $3.1 million in the third quarter of 2008.

GAAP EPS amounted this quarter to a loss of $0.20 per basic and diluted share, compared to a loss of $0.20 per basic and diluted share in the second quarter of 2009, and earnings per basic and diluted share of $0.08 in the third quarter of 2008. On a non-GAAP basis, the result for the third quarter is equivalent to a loss of $0.17 per basic and diluted share, compared to earnings per basic and diluted share on a non-GAAP basis of $0.11 in the third quarter of 2008.

Commenting on the results and developments in the third quarter, Syneron CEO Lou Scafuri said, “I am pleased with the results for the third quarter, especially the strong improvement in our gross margin during the past nine months, our return to a positive cash flow from operating activities, and the sequential improvement in revenue in the third quarter which, traditionally, is the weakest quarter for the aesthetic device sector. The continued improvement in the gross margin and the positive turn in cash flow from operations reflect, primarily, the success of deep company-wide restructuring, while the sequential increase in revenue, although modest, is evidence of physician acceptance of the new products we have introduced to the market since the start of the year. These sales figures are also encouraging because they support the indications of gradually improving demand for procedures and devices which we have begun receiving from our luminary doctors and major customers.

“The economic challenges of the past year,” Mr. Scafuri continued, “have been the catalyst for dynamic change across markets, our sector clearly included. The aesthetic industry was impacted by the economic downturn and credit tightening, but I believe we are emerging as a much stronger sector and I am proud that Syneron is leading that change, most significantly with our announcement in September of the contemplated merger between Syneron and Candela Corporation. We have also led with the launch of several new products which offer a new business model suitable to today’s market requirement for an enhanced value proposition, as well as efficacy and less patient down time. These products include the unique and innovative eMatrix™, which has been well received by physicians, and is based on a new paradigm of treatment aimed at transforming the sector into one that is significantly more flexible and responsive to changing patient and physician criteria for less invasive yet highly efficacious aesthetic treatments.”

Syneron emerged out of the third quarter with a significantly stronger balance sheet. Syneron’s cash position (including long-term deposits) totaled $213.3 million as of September 30, 2009 and Syneron continues to have no debt. Trade receivables, net, decreased to $16.8 million as of September 30, 2009 from $32.6 million at the end of 2008. Inventories fell for the third consecutive quarter to $9.7 million, representing a 24% decline since December 31, 2008. Shareholders’ equity at the end of the third quarter of 2009 was $228.1 million.

Commenting on the improved financial position, CFO Fabian Tenenbaum said, “The continued improvement in the balance sheet in the third quarter reflects enhanced processes and controls introduced as part of the restructuring program. Combined with the streamlining of operations and cost savings, these better financial controls will place Syneron in a favorable position as the rise in macroeconomic activity positively impacts the aesthetic medical device industry.”

Conference call

Syneron management will host its third quarter earnings conference call today at 8:30am ET. Syneron will be broadcasting live via the Investor Relations section of its website, www.syneron.com. To access the call, enter the Syneron website, then click on the Investors Relations Overview and select “Q3 2009 Results Conference Call.” Participants are encouraged to log on at least 15 minutes prior to the conference call in order to download the applicable audio software. The call can be heard live or with an on-line replay which will follow. Those interested in participating in the call and the question and answer session should dial (toll free): 888-211-7360 in the U.S., and 913-312-0959 from overseas.

Use of Non-GAAP Measures

This press release provides financial measures for net loss, net loss per diluted share, net profit and net profit per diluted share, which exclude an expense charge related to stock-based compensation and are therefore not calculated in accordance with generally accepted accounting principles (GAAP). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance because it reflects our operational results and enhances management’s and investors’ ability to evaluate the Company’s net profit and net profit per diluted share. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when evaluating the business internally and, therefore, felt it important to make these non-GAAP adjustments available to investors. A reconciliation of each GAAP to non-GAAP financial measure discussed in this press release is contained in the accompanying financial tables.

About Syneron

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light. Syneron’s innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron are located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters and Logistics Support in Irvine, CA, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to future events or Syneron’s future performance, including statements with respect to Syneron’s expectations regarding, but not limited to Syneron’s profitability and maintaining a leadership position in core markets. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Syneron’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward-looking statements, including, but not limited to the risks associated with Syneron’s ability to operate under the difficult conditions of the current global economy; the risk associated with Syneron’s ability to commercialize new products and identify new markets for Syneron’s technology; ability to manage Syneron’s growth, competition and pricing pressure; risks associated with Syneron’s international operations; risks associated with Syneron’s collaboration with Procter & Gamble; risks associated with regulatory qualifications or approvals; risks related to Syneron’s intellectual property; risks related to Syneron’s operations in Israel; the ability of each of Syneron and Candela to satisfy the closing conditions and consummate the merger transaction, including obtaining the approval of the transaction by Candela’s stockholders; the risk that the businesses of Syneron and Candela may not be coordinated successfully; the risk that the merger transaction of Syneron and Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected and the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers. Further information regarding these and other risks relating to Syneron’s business, including the operations of Candela, is set forth under the heading “Risk Factors” in Syneron’s registration statement on Form F-4, filed with the Securities and Exchange Commission (the “SEC”) on October 28, 2009 and in other reports filed with the SEC. These factors are updated from time to time through the filing of reports and registration statements with the SEC. Syneron does not assume any obligation to update the forward-looking information contained in this press release.

IMPORTANT ADDITIONAL INFORMATION

In connection with the combination of Syneron and Candela pursuant to an Agreement and Plan of Merger (the “Merger”), Syneron has filed with the SEC a registration statement on Form F-4, which includes a proxy statement of Candela and a prospectus of Syneron and other relevant materials in connection with the proposed transactions. Candela has also filed the same proxy statement/prospectus with the SEC. Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials (when they become available) because these materials will contain important information about Syneron, Candela, and the proposed transaction. The proxy statement/prospectus and the other relevant materials (when they become available), and any and all documents filed with the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, free copies of the documents filed with the SEC by Syneron will be available on the investor relations portion of Syneron’s website at www.syneron.com. Free copies of the documents filed with the SEC by Candela will be available on the investor relations portion of Candela’s website at www.candelalaser.com. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT MATERIALS (WHEN THEY BECOME AVAILABLE) BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS.

Syneron, the Syneron logo, and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. elos (Electro-Optical Synergy) is a proprietary technology of Syneron Medical Ltd. All other names are the property of their respective owners.

 Syneron Medical Ltd. CONSOLIDATED STATEMENTS OF INCOME U.S. dollars in thousands, except per share data Three Months ended Nine Months ended September 30, September 30, 2009 2008 2009 2008 (unaudited)(unaudited)(unaudited)(unaudited) ---------- ---------- ---------- --------- Revenues 14,279 28,493 40,323 100,805 Cost of Revenues 4,705 7,026 14,664 23,252 ---------- ---------- ---------- --------- Gross Profit 9,574 21,467 25,659 77,553 Operating expenses: Research and development 3,063 3,646 8,949 10,633 Selling and marketing 7,531 13,259 26,287 41,548 General and administrative 4,225 2,684 13,059 9,924 Legal settelement, net of legal cost - - (3,975) - ---------- ---------- ---------- --------- Total operating expenses 14,819 19,589 44,320 62,105 ---------- ---------- ---------- --------- Operating (Loss) Income (5,245) 1,878 (18,661) 15,448 Financial Income, net 447 529 1,661 3,226 ---------- ---------- ---------- --------- Income (Loss) before taxes on income (4,798) 2,407 (17,000) 18,674 Taxes on income 858 219 2,455 (2,825) ---------- ---------- ---------- --------- Income (Loss) before non controlling interest (5,656) 2,188 (19,455) 21,499 Net loss attributable to non controlling interest 107 - 213 - ---------- ---------- ---------- --------- Net (Loss) income attributable to Syneron shareholders (5,549) 2,188 (19,242) 21,499 Basic net (Loss) Income per share (0.20) 0.08 (0.70) 0.78 Diluted net (Loss) Income per share (0.20) 0.08 (0.70) 0.78 ========= ========= ========= ======== Weighted average number of shares used in per share calculation (in thousands): Basic 27,530 27,436 27,505 27,394 Diluted 27,530 27,503 27,505 27,518 ========= ========= ========= ======== Syneron Medical Ltd. CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands September 30, December 31, 2009 2008 (unaudited) (audited) ------------- ------------- CURRENT ASSETS Cash and cash equivalents (*) 32,282 72,366 Short term bank deposit (*) 1,923 - Available-for-sale marketable securities (*) 156,868 117,342 Trade receivables 16,759 32,637 Other accounts receivables and prepaid expenses 2,064 4,249 Inventories 9,668 12,660 ------------- ------------- Total Current Assets 219,564 239,254 LONG-TERM ASSETS Severance pay fund 209 107 Long-term deposits and others (*) 209 180 Long-term available-for-sale marketable securities (*) 22,022 27,214 Investments in affiliated companies 3,300 4,225 Property and equipment, net 2,940 3,656 Intangible assets, net 5,412 3,828 Goodwill 4,251 2,822 ------------- ------------- Total Long-Term Assets 38,343 42,032 ------------- ------------- Total Assets 257,907 281,286 ============= ============= CURRENT LIABILITIES Trade Payables 3,582 8,675 Other accounts payable and accrued expenses 22,748 25,587 ------------- ------------- Total Current Liabilities 26,330 34,262 LONG-TERM LIABILITIES Deferred Revenues 2,367 3,140 Warranty Accruals 803 1,117 Accrued severance pay 307 171 ------------- ------------- Total Long-Term Liabilities 3,477 4,428 EQUITY 228,100 242,596 ------------- ------------- Total Liabilities and Equity 257,907 281,286 ============= ============= (*) Total Cash and Liquid Investments 213,304 217,102 Syneron Medical Ltd. CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands Three Months ended Nine Months ended September 30, September 30, 2009 2008 2009 2008 (unaudited) (unaudited) (unaudited) (unaudited) ----------- ----------- ----------- ---------- CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) income before non controlling interest (5,656) 2,188 (19,455) 21,499 Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: Depreciation and amortization 355 453 1,509 1,250 Deferred taxes, net 550 - 1,366 - Increase (decrease) in accrued severance pay, net 4 (2) 13 39 Decrease (increase) in trade receivables 2,098 (1,337) 15,878 (4,028) Decrease (increase) in other accounts receivables and prepaid expenses 9 (163) 831 1,847 Decrease (increase) in inventories 823 (405) 3,161 (2,659) Increase (decrease) in trade payables 811 (1,436) (5,160) (979) Increase (decrease) in other account payables and accrued expenses 1,247 395 (842) (1,436) Impairments of available-for-sale marketable securities 36 350 208 467 Realized loss, changes in accrued interest and amortization of premium on marketable securities 333 279 1,322 191 Equity based compensation 738 895 3,427 5,400 Decrease in deferred revenues and warranty accruals (986) (1,052) (3,161) (494) ----------- ----------- ----------- ---------- Net cash provided by (used in) operating activities 362 165 (903) 21,097 ----------- ----------- ----------- ---------- CASH FLOWS FROM INVESTING ACTIVITIES Maturity (purchase) of short-term deposits, net (130) - (1,923) 1,000 Purchase of available-for-sale marketable securities (100,870) (33,125) (247,368) (180,439) Proceeds from sale and redemption of available-for-sale marketable securities 90,380 15,556 211,565 140,856 Payments for investments in Affiliated Companies (350) (723) (750) (1,303) Net cash paid in conjunction with acquisition of a subsidiary - - (41) - Acquisition of minority shares in a subsidiary (16) (40) (440) (40) Investment in long-term deposits and others (35) (37) (22) (50) Purchase of property and equipment (175) (318) (396) (830) ----------- ----------- ----------- ---------- Net cash used in investing activities (11,196) (18,687) (39,375) (40,806) ----------- ----------- ----------- ---------- CASH FLOWS FROM FINANCING ACTIVITIES Repurchase of ordinary shares from shareholders at cost - - - (1,927) Issuance of shares as a result of exercise of options and RSU’s 193 1 194 4 ----------- ----------- ----------- ---------- Net cash provided by (used in) financing activities 193 1 194 (1,923) ----------- ----------- ----------- ---------- Decrease in cash and cash equivalents (10,641) (18,521) (40,084) (21,632) Cash and cash equivalents at the beginning of the period 42,923 39,513 72,366 42,624 ----------- ----------- ----------- ---------- Cash and cash equivalents at the end of the period 32,282 20,992 32,282 20,992 ----------- ----------- ----------- ---------- Syneron Medical Ltd. Reconciliation Between GAAP To Non-GAAP Consolidated Statement Of Income U.S. dollars in thousands, except per share data Three Months ended Nine Months ended September 30, September 30, 2009 2008 2009 2008 (unaudited) (unaudited) (unaudited) (unaudited) ----------- ----------- ----------- ----------- Operating (Loss) Income (GAAP) (5,245) 1,878 (18,661) 15,448 Non-GAAP adjustment: Stock based compensation 738 895 3,427 5,400 ----------- ----------- ----------- ----------- Non-GAAP operating (Loss) Income (4,507) 2,773 (15,234) 20,848 Net (Loss) Income (GAAP) (5,549) 2,188 (19,242) 21,499 Non-GAAP adjustment: Stock based compensation 738 895 3,427 5,400 ----------- ----------- ----------- ----------- Non-GAAP Net (Loss) Income (4,811) 3,083 (15,815) 26,899 Non-GAAP net (Loss) Income per share : Basic net (Loss) Income per share (0.17) 0.11 (0.57) 0.98 Diluted net (Loss) Income per share (0.17) 0.11 (0.57) 0.97 Weighted average number of shares used in per share calculation (in thousands): Basic 27,530 27,436 27,505 27,394 Diluted 27,530 27,695 27,505 27,751 ========= ========= ========= =========